Risk factor
Good trading liquidity
Profitability factor
Favourable analyst view
About
Sinocare Inc. engages in the development, manufacture, and marketing of rapid diagnosis testing products primarily in the People’s Republic of China. It offers blood glucose and pressure monitors; point of care testing products; digital management tool solutions; non-invasive screening products; and PTS and Trividia products. The company provides its products for the patients with chronic diseases and diabetes, as well as for healthcare professionals. It also exports its products. The company was founded in 2002 and is based in Changsha, the People’s Republic of China.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBI
Target Price
The average target price of 300298.SZ is 22.4 and suggests 34.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to